Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE ISSUED BY THE COMPANY ON FEBRUARY 12, 2015 - ALBIREO PHARMA, INC. | exhibit99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549
______________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): February 12, 2015
BIODEL
INC.
(Exact name of
registrant as specified in its charter)
Commission File Number 001-33451
| Delaware | 90-0136863 |
| (State or other jurisdiction of incorporation or organization) | (IRS Employer Identification Number) |
| 100 Saw Mill Road | |
| Danbury, Connecticut | 06810 |
| (Address of principal executive offices) | (Zip code) |
(203)
796-5000
(Registrant's
telephone number, including area code)
| Not Applicable |
| (Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
[ ] |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
[ ] |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
[ ] |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
[ ] |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 Results of Operations and Financial Condition.
On February 12, 2015, Biodel Inc. (the "Company") issued a press release (the “Press Release”) announcing its financial results for its first fiscal year quarter ended December 31, 2014. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act except as expressly set forth by specific reference in such a filing.
| Item 9.01 | Financial Statements and Exhibits. |
|
(d) |
Exhibits. |
|
The following exhibit relating to Item 2.02 shall be deemed to be furnished and not filed: | |
|
99.1 Press Release issued by the Company on February 12, 2015. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: February 12, 2015 | BIODEL INC. | ||
| By: | /s/ Paul S. Bavier | ||
| Paul S. Bavier, General Counsel and Secretary | |||
3
EXHIBIT INDEX
| Exhibit No. | Description | ||
| 99.1 | Press Release issued by the Company on February 12, 2015. | ||
4